Clinical applications and challenges of CD40/CD40L signaling regulation in autoimmune diseases - Takeaways - MDSpire

Clinical applications and challenges of CD40/CD40L signaling regulation in autoimmune diseases

  • By

  • Yangyang Man

  • Xiaoni Chen

  • Yi Liu

  • Biao Zhang

  • Jiahua Hu

  • Xianliang Hou

  • May 18, 2026

Share

  • 1

    The CD40/CD40L axis is crucial for linking innate and adaptive immunity, influencing autoimmune inflammation.

  • 2

    Dysregulated CD40/CD40L signaling is implicated in autoimmune diseases like rheumatoid arthritis and systemic lupus erythematosus.

  • 3

    Therapeutic targeting of CD40/CD40L must consider cell-specific signaling to enhance safety and efficacy.

  • 4

    Both membrane-bound and soluble forms of CD40L can activate CD40, affecting immune responses and inflammation.

  • 5

    Safety challenges, including thromboembolic events, have emerged in early trials of CD40/CD40L-targeted therapies.

Original Source(s)

Clinical applications and challenges of CD40/CD40L signaling regulation in autoimmune diseases

  • by Yangyang Man, Xiaoni Chen, Yi Liu, Biao Zhang, Jiahua Hu, Xianliang Hou

  • May 18, 2026

Related Content

Neoadjuvant Single-Cycle Pembrolizumab for Stage I to III dMMR Colon Cancer

In a Danish phase II trial (RESET-C) reported in the Journal of Clinical Oncology, Gögenur et al found that a single cycle of neoadjuvant pembrolizumab was associated with pathologic complete response...

Study Finds Prostate Cancer Overdiagnosis Rises ‘Substantially’ With Age

Investigators have found that overdiagnosis of prostate cancer through prostate-specific antigen screening is low in younger men—but rises sharply with age.

FDA Approves Fam-Trastuzumab Deruxtecan-nxki Indications in HER2-Positive Early Breast Cancer

On May 15, 2026, the U.S. Food and Drug Administration (FDA) approved fam-trastuzumab deruxtecan-nxki (Enhertu) for two separate indications for the treatment of adult patients with HER2-positive earl...